Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00290
|
|||||
| Drug Name |
Lopinavir
|
|||||
| Synonyms |
A 157378; A 157378.0; A-157378-0; A-157378.0; ABT 157378; ABT 378; ABT-378; ABT-378, LOPINAVIR; AIDS032937; Aluvia (TN); Aluviran; Kaletra (TN); Koletra; LPV; Lopinavir (JAN/USAN/INN); Lopinavir [USAN:INN:BAN]; RS-346
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Human immunodeficiency virus infection [ICD11:1C62.Z] | Approved | [1] | |||
| Therapeutic Class |
Anti-HIV Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C37H48N4O5
|
|||||
| Canonical SMILES |
CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O
|
|||||
| InChI |
InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1
|
|||||
| InChIKey |
KJHKTHWMRKYKJE-SUGCFTRWSA-N
|
|||||
| CAS Number |
CAS 192725-17-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 628.8 | Topological Polar Surface Area | 120 | ||
| Heavy Atom Count | 46 | Rotatable Bond Count | 15 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
5.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10225535
,103198077
,104178992
,104408196
,11108093
,11528784
,123080504
,124757206
,124893167
,125164010
,126522368
,126655919
,126665841
,127310211
,127310212
,127310213
,127338643
,127338644
,127338645
,134337997
,135051036
,136283935
,136367896
,14912304
,14912305
,26737285
,26757998
,44423527
,46392556
,46508588
,49853992
,50086984
,50096471
,50096475
,50111692
,53812811
,53812974
,56310583
,57335304
,583260
,615079
,76999753
,7848488
,7885634
,7979791
,826916
,841952
,87557375
,87557376
,99437252
|
|||||
| ChEBI ID |
ChEBI:31781
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [3] | ||
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [4] | ||
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [5] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [4] | ||
| References | ||||||
| 1 | Lopinavir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
| 3 | Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother. 2007 Nov;60(5):987-93. | |||||
| 4 | Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol. 2010 Jul;160(5):1224-33. | |||||
| 5 | Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.